ILMN vs. RGC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ILMN and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ILMN | RGC |
|---|---|---|
| Company Name | Illumina, Inc. | Regencell Bioscience Holdings Limited |
| Country | United States | Hong Kong |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 15.53 billion USD | 9.59 billion USD |
| Exchange | NasdaqGS | NasdaqCM |
| Listing Date | July 28, 2000 | July 16, 2021 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ILMN and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ILMN | RGC |
|---|---|---|
| 5-Day Price Return | 6.37% | 26.66% |
| 13-Week Price Return | 3.98% | 3.83% |
| 26-Week Price Return | 28.87% | 3,133.87% |
| 52-Week Price Return | -25.92% | 18,127.27% |
| Month-to-Date Return | 6.37% | 29.77% |
| Year-to-Date Return | -24.40% | 15,323.08% |
| 10-Day Avg. Volume | 1.78M | 0.24M |
| 3-Month Avg. Volume | 1.96M | 1.00M |
| 3-Month Volatility | 43.73% | 90.19% |
| Beta | 1.41 | 2.26 |
Profitability
Return on Equity (TTM)
ILMN
55.15%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
ILMN’s Return on Equity of 55.15% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
RGC
-54.75%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
ILMN
29.37%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
A Net Profit Margin of 29.37% places ILMN in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.
RGC
--
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
Net Profit Margin data for RGC is currently unavailable.
Operating Profit Margin (TTM)
ILMN
30.21%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
An Operating Profit Margin of 30.21% places ILMN in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
RGC
--
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
Operating Profit Margin data for RGC is currently unavailable.
Profitability at a Glance
| Symbol | ILMN | RGC |
|---|---|---|
| Return on Equity (TTM) | 55.15% | -54.75% |
| Return on Assets (TTM) | 20.47% | -51.38% |
| Net Profit Margin (TTM) | 29.37% | -- |
| Operating Profit Margin (TTM) | 30.21% | -- |
| Gross Profit Margin (TTM) | 67.09% | -- |
Financial Strength
Current Ratio (MRQ)
ILMN
1.81
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
ILMN’s Current Ratio of 1.81 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
RGC
42.68
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
Debt-to-Equity Ratio (MRQ)
ILMN
0.88
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
ILMN’s leverage is in the upper quartile of the Life Sciences Tools & Services industry, with a Debt-to-Equity Ratio of 0.88. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
RGC
0.00
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
ILMN
-2.28
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
ILMN has a negative Interest Coverage Ratio of -2.28. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
RGC
--
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
Interest Coverage Ratio data for RGC is currently unavailable.
Financial Strength at a Glance
| Symbol | ILMN | RGC |
|---|---|---|
| Current Ratio (MRQ) | 1.81 | 42.68 |
| Quick Ratio (MRQ) | 1.28 | 41.89 |
| Debt-to-Equity Ratio (MRQ) | 0.88 | 0.00 |
| Interest Coverage Ratio (TTM) | -2.28 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ILMN
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
ILMN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ILMN
0.00%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
ILMN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
RGC
0.00%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ILMN | RGC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ILMN
12.44
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
In the lower quartile for the Life Sciences Tools & Services industry, ILMN’s P/E Ratio of 12.44 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
RGC
--
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
P/E Ratio data for RGC is currently unavailable.
Price-to-Sales Ratio (TTM)
ILMN
3.65
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
ILMN’s P/S Ratio of 3.65 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RGC
--
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
P/S Ratio data for RGC is currently unavailable.
Price-to-Book Ratio (MRQ)
ILMN
6.69
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
ILMN’s P/B Ratio of 6.69 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
RGC
9.57
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | ILMN | RGC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 12.44 | -- |
| Price-to-Sales Ratio (TTM) | 3.65 | -- |
| Price-to-Book Ratio (MRQ) | 6.69 | 9.57 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.18 | -- |